News

PIR International was delighted to partner with Lidia Pieri and the Board at Sibylla Biotech on the appointment of Dieter Weinand as Chairman of the Board of Directors. Sibylla is a preclinical stage company focused on developing small molecule degraders with a novel Mechanism of Action to find new therapeutics for unmet medical needs. Their platform is powered by computer simulations and AI methods, which enables the discovery and development of compounds that induce the degradation of a target protein by interfering with its folding pathway. Dieter is an industry veteran, boasting over 35 years in the pharmaceutical sector, including [...]

PIR International was delighted to partner with Dr Neil Torbett and the Board at PhoreMost on the appointment of Barbara Duncan as Chair and Stephen Dilly as Non-Executive Director. PhoreMost is a UK-based biopharmaceutical company pioneering next-generation drug discovery through its proprietary SITESEEKER® platform. By exploiting the inherent complexity of protein shape diversity, PhoreMost identifies novel and unanticipated druggable targets across a wide range of diseases. The company’s approach accelerates the development of new therapeutics by linking phenotype-driven screening with actionable drug discovery, opening up vast untapped areas of the human proteome to drug development. Barbara Duncan is an accomplished [...]

PIR International is pleased to announce the appointment of Robert (Bob) Radie as Non-Executive Chair and Heather Preston as Advisory Board Member at Monument Therapeutics. Monument Therapeutics is a neuroscience-focused drug development company headquartered in Manchester, UK. It applies a unique novel drug development strategy, leveraging digital assessments of cognition to select patients suitable for treatment with new innovative drugs. Bob brings over 30 years of leadership experience in both public and private pharmaceutical and biotech companies. Early in his career at Eli Lilly, he contributed to the successful launch of blockbuster antidepressant and antipsychotic drugs, inspiring his sustained focus [...]

As we approach the end of 2023, we are pleased to share a selection of recently completed appointments and initiated searches with our valued clients.

PIR International is pleased to announce the appointment of Beverley Carr as Chief Business Officer at CHARM Therapeutics. CHARM Therapeutics is a protein-ligand intelligence company turning advanced protein-ligand prediction into impactful medicines. CHARM’s advanced protein-ligand prediction platform, DragonFold, provides unique 3D insights into the dynamic structure of the protein-ligand binding interactions, with the potential for profound impacts on the design of novel molecules and delivery of new medicines. Beverley brings extensive business development experience, with a career spanning over a decade at GSK and several leading biotechnology companies. She joins CHARM from Amphista Therapeutics, where she served as Interim Chief [...]

PIR International is pleased to announce the appointment of Luba Greenwood as Non-Executive Chair at Closed Loop Medicine. Closed Loop Medicine is a TechBio company enhancing drug development through AI, machine learning, and personalized dosing, to bring forward the promise of precision care. The Company’s proprietary platform enhances treatment options by seamlessly integrating drugs and devices with patient-led digital experiences and closed-loop models of care – all under a single prescription. Working in combination with an expanding portfolio of new and established medicines, Closed Loop Medicine’s scalable approach to treating the individual, not just the disease, has the potential to [...]

PIR International is pleased to announce the appointment of Dieter Weinand as Non-Executive Chair at Anaveon. Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. The Company was founded in 2017 by scientists and industry experts, who aspire to invent and develop therapeutic treatments that benefit patients and society. The organisation’s mission is to harness the power of the immune system for life-saving treatments. Dieter is an experienced business leader in the pharmaceutical industry and is the former Chair and CEO of Bayer Pharmaceuticals. During a career stretching back [...]

As we approach the end of 2023, we are pleased to share a selection of recently completed appointments and initiated searches with our valued clients.

PIR International is pleased to announce the placement of Giles Brown as SVP of Chemistry at Amphista Therapeutics. Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, is applying its proprietary degrader platform to advance new approaches in TPD. The Company aims to address the challenges faced by earlier stage TPD research and transform the lives of patients with severe diseases including cancer and central nervous system diseases. Giles joins Amphista with over 20 years’ experience in medicinal chemistry during which he contributed to the discovery and development of fifteen preclinical candidates, of which seven successfully entered [...]

PIR International is pleased to announce the placement of Daniel Brennan as SVP, Corporate and Commercial Strategy at NMD Pharma. NMD Pharma A/S is a clinical-stage biotech company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. Daniel joins NMD Pharma with over 25 years of strategic commercial experience in the biopharmaceutical industry, having held various senior management roles across the sector. During his career to date, he has led the development of commercial strategies and plans for over 20 biopharmaceutical products across neuroscience, rare disease and hospital products, including 5 successful US product launches in rare [...]